The many talents of bispecific antibodies

Medicine Bispecific antibodies (bsAbs) bind two different molecules, and this dual specificity offers numerous approaches to therapeutic targeting. There are more than 100 bsAbs in clinical development. These are mostly for cancer, but neurodegenerative, inflammatory, autoimmune, and vascular diseases are increasingly considered as areas in which bsAbs could provide therapeutic solutions. In a Perspective, Brinkmann and Kontermann discuss the general modes of action of these biologics and clinical progress in various diseases. There are hurdles to overcome, including ensuring safety and engineering for greater efficacy. With a plethora of bsAb designs and modes of action, the focus is becoming what to target and how best to do so. Science , abg1209, this issue p. [916][1] [1]: /lookup/doi/10.1126/science.abg1209